The inhibition of HAS3 or CD44 in vivo significantly decreased the glioma volumes, extended the survival time of mice, and downregulated Ki67 expression compared with controls (Fig. 2E–G, Supplementary Fig. 2F–G). Here, CD44 is linked to central nervous system cancer.